Clinical Trials Logo

Clinical Trial Summary

This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04939246
Study type Interventional
Source Baptist Health South Florida
Contact
Status Active, not recruiting
Phase N/A
Start date June 18, 2021
Completion date August 2025

See also
  Status Clinical Trial Phase
Recruiting NCT02605811 - Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer Phase 2
Terminated NCT02960282 - Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Completed NCT01320241 - Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture Phase 2
Completed NCT02192346 - α-TEA in Advanced Cancer Phase 1
Completed NCT01469598 - Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer Phase 2
Active, not recruiting NCT04376502 - Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma. N/A
Active, not recruiting NCT02730923 - Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) Phase 1/Phase 2